ClinicalTrials.gg
Enrolling by invitationNCT07035132NORMAUpdated Oct 7, 2025

Impact of Specific Oligomeric Supplementation in Oncologic Patients Undergoing Radiotherapy With Malnutrition or at Risk.

An observational study in Malnutrition in Elderly, Oncological Patients and Digestive Disorders, sponsored by Outcomes'10. Enrolling by invitation at 4 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by Outcomes'10 · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
132
Ages
18 Years and older
Sex
All
01

Study summary

An observational, prospective, multicenter study to be conducted in 5 hospitals in Spain. Patients with cancer undergoing radiotherapy are malnourished or at risk of malnutrition. Due to the characteristics of their pathology or gastrointestinal disorders, the use of oligomeric nutritional formulas formulated with 100% hydrolyzed whey lactoprotein and a high MCT content is recommended as part of routine clinical practice. Patients will be followed for 12 weeks, with three visits: a baseline visit upon inclusion in the study, after 6 weeks and a final visit 12 weeks after the nutritional treatment starts.

Read the detailed description

The prevalence of malnutrition is high in cancer patients: about 80% of patients will suffer from malnutrition at some point, and it is the cause of 10-20% of deaths in this type of patient.

To address malnutrition in these patients, international clinical guidelines recommend periodically reviewing their nutritional status and supplementing with oral nutrition formulas (ONS) when they are unable to meet their nutritional needs from their usual diet.

The ONSs have a nutrient composition designed to meet the specific needs of the patient, but there are pathologies, types of tumours and treatments, such as radiotherapy, chemotherapy, immunotherapy and others that can alter the digestion process, making it difficult for the gastrointestinal tract to utilise nutrients. Patients with these pathologies often cannot tolerate polymeric SNO formulations and require oligomeric peptide-based diet (PBD) formulations.

PBDs contain hydrolysed proteins in the form of peptides and medium-chain triglycerides (MCTs), which are more easily assimilated, helping patients to reduce weight loss and improve overall nutritional status. In addition, they contain hydrolysed serum lactoprotein with high biological quality that stimulates the formation of muscle tissue, minimising cachexia.

Radio/chemotherapy/immunotherapy treatment has negative effects on the nutritional and functional status of cancer patients, which also makes them more susceptible to the toxicities of cancer treatments and clinical complications. It has been shown that these patients tolerate PBD formulas well and even reduce their baseline intestinal symptoms, which facilitates compliance with nutritional treatment. However, adherence to these treatments remains a challenge as it is not always optimal, resulting in the non-achievement of the potential benefits.

The main objective of the study is to evaluate the effects of a hypercaloric SNO, with 100% hydrolysed serum lactoprotein and high MCT intake, in cancer patients undergoing radiotherapy, malnourished or at risk of malnutrition, in terms of improving the patient's nutritional status after 12 weeks of treatment.

02

Conditions studied

  • Malnutrition in Elderly
  • Oncological Patients
  • Digestive Disorders

Keywords

  • nutritional supplementation
  • radiotherapy
  • malabsortion
  • oligomeric formula
03

In context

Digestive System Diseases

406 studies on the registry are indexed under Digestive System Diseases; 79 are open to participants now.

This study's planned enrollment of 132 is below the median of 399 across 104 observational studies indexed under Digestive System Diseases.

Browse Digestive System Diseases studies →

Lead sponsor

Outcomes'10 is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Oncological patients undergoing radiotherapy, who present malnutrition or risk of malnutrition and due to the characteristics of the pathology or gastrointestinal alterations, the use of oligolimeric nutritional formulas formulated with 100% hydrolyzed serum lactoprotein and high MCT content is recommended within the usual clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of legal age (≥18 years).
  • Oncology patients (with head and neck, lung or rectal cancer) undergoing or about to start radiotherapy treatment. Patients with oesophageal cancer will also be included, as long as the patient is not undergoing PEG.
  • Patients who are malnourished or at risk of malnutrition according to GLIM criteria.
  • Patients requiring supplementation with an oligomeric formula with 100% hydrolysed serum lactoprotein and high MCT intake due to gastrointestinal disturbances (either maldigestion or maldigestion, malabsorption or dysmotility) intolerance to polymeric formulations or any other reason as considered by the physician.
  • Patients who, at the discretion of the investigator, have the ability to answer the questionnaires and follow the procedures detailed in the protocol.
  • Patients who give written to participate.

Exclusion criteria

Exclusion Criteria:

  • Patients with galactosemia, allergies and/or intolerances to lactose or any of the compounds of the formula.
  • Patients receiving nutritional support other than that of the study characteristics or who have received it during the last month. It will be accepted in patients who, being on a polymeric SNO, are advised to change to the oligomeric formula under study, due to gastrointestinal alterations, intolerances or any other reason considered by the doctor.
  • Patients who have undergone surgery in the last three months.
  • Patients who have received Enteral Nutrition in the last 3 months for SNG/SNJ/PEG.
  • Pregnant or lactating women.
  • Patients with advanced renal or hepatic disease (with less than 45 ml/min or CP=C).
  • Patients with advanced neoplastic disease with \<3 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
132 participants (estimated)
Patient registry
No

Interventions

  • Dietary supplementOral supplementation with nutritional oligomeric formula

    Patients will be supplemented with the specific oligomeric formula (1 or 2 bottles/day, as per investigator's decision) during, at least, the 12 weeks of the study follow-up.

06

What researchers measure

Primary outcomes

  1. Percentage of patients who improve the degree of malnutrition.

    According to body weight, after 12 weeks of treatment with SNO with 100% hydrolyzed serum lactoprotein and high MCT intake.

    Time frame: From enrollment to the end of treatment at 12 weeks

Secondary outcomes

  1. Percentage of patients with improvement in the degree of malnutrition

    According to GLIM criteria after 12 weeks of treatment with SNO with 100% hydrolyzed serum lactoprotein and high MCT intake.

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Percentage change in BMI

    Weight and height will be combined to report BMI in kg/m².

    Time frame: From enrollment to the end of treatment at 12 weeks

  3. Arm circumference

    Is measured in CM

    Time frame: From enrollment to the end of treatment at 12 weeks

  4. Calf circumference

    Is measured in CM

    Time frame: From enrollment to the end of treatment at 12 weeks

  5. Maximum prehensile strength value

    Using a dynamometer, an instrument that measures force in kilograms.

    Time frame: From enrollment to the end of treatment at 12 weeks

  6. Sit-to-stand test

    Is measured primarily by counting the number of repetitions a person can perform while standing up and sitting in a chair in a specified period of time, such as 30 seconds.

    Time frame: From enrollment to the end of treatment at 12 weeks

  7. Impedancemetry values

    Probe.

    Time frame: From enrollment to the end of treatment at 12 weeks

  8. Percentage of patients presenting complications associated with nutritional status during treatment.

    Changes in oncological treatment, hospital admissions or visits to the emergency room are considered complications.

    Time frame: From enrollment to the end of treatment at 12 weeks

  9. Percentage of patients presenting changes in gastrointestinal tolerance after 6 and after 12 weeks of treatment with SNO with 100% hydrolyzed serum

    After 6 and after 12 weeks of treatment with SNO with 100% hydrolyzed serum lactoprotein and high MCT intake.

    Time frame: After 6 and after 12 weeks of treatment

  10. Distribution of the patients according to their compliance with the treatment

    With SNO with 100% hydrolyzed serum lactoprotein and high MCT intake.

    Time frame: At 6 and 12 weeks of treatment.

  11. Distribution of the patients according to their adherence to the treatment

    (low: 0-2 points, medium: 3-4 points or high: 5-6 points)

    Time frame: At 6 and 12 weeks of treatment.

  12. Percentage of patients who maintain or improve their quality of life after 12 weeks of treatment.

    Improve their quality of life.

    Time frame: After 12 weeks of treatment.

  13. Percentage of patients satisfied with the product

    With SNO with 100% hydrolyzed serum lactoprotein and high MCT content.

    Time frame: After 12 weeks of treatment with SNO

  14. Average health care expenditure per patient, according to degree of malnutrition, during the study.

    Health expenditure per patient

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2025, 4 months after the start.

Of 44 non-industry observational studies under Digestive System Diseases, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 114. This study's planned 4 months is below that.

Counting every sponsor, half of 55 studies reached it within 42 months; a quarter within 15 and three quarters within 102.

Digestive System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
Jun 24, 2025
StartActual
Aug 15, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07035132
Lead sponsor
Outcomes'10
Collaborators
Nestlé Health Science Spain
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
Aug 15, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Oct 7, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion